TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05089903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bulk Order
Description: A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bulk Order
Description: A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Endorsement
Description: Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Endorsement
Description: Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Bulk Order
Description: The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Bulk Order
Description: The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Endorsement
Description: Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Endorsement
Description: Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.
Study: NCT06203080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ancetate gel
Description: An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonoxinol gel
Description: The nonoxinol gel produced by China Pharmaceutical University Pharmacy Co., Ltd will be utilized for the intervention. Each product weighs 5 g and contains 50 mg of N-9. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
Study: NCT06236009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-004
Description: TAK-004 subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching- placebo subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching- placebo subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching- placebo subcutaneous injections.
Study: NCT06484543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maslinic Acid
Description: Consumption of Maslinic Acid for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consumption of Placebo for 12 weeks
Study: NCT04834388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra treatment is started within 8 hours of symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra treatment is started within 8 hours of symptom onset
Study: NCT06547996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tES-tDCS group
Description: 2mA/20mins/session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tES-tACS group
Description: 2mA/40Hz/20mins/session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tES-sham group
Description: 0mA/20mins/session
Study: NCT05132582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg given by mouth (orally) twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420mg given by IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 420mg given by IV every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination product: Trastuzumab + Pertuzumab
Description: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination product: Trastuzumab + Pertuzumab
Description: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given orally twice daily
Study: NCT04803708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TP-102
Description: One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
Study: NCT05192031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation support
Description: Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
Study: NCT06107062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol - fsCBD
Description: Full-spectrum (i.e., fsCBD, 7.8mg THC (3.4mg BID)), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol - bsCBD
Description: Broad-spectrum (i.e., bsCBD, 0% THC), plant-derived CBD capsules produced by Ecofibre/Ananda Hemp will be used
Study: NCT06399705

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting
Description: Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
Study: NCT05258058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory and Adaptation Training-Geriatrics
Description: MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
Study: NCT06192589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice daily for 28 days in Part 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be administered once at 15 mg on days 1, 4, and 11.
Study: NCT05684523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valerian-Hop Extract
Description: herbal drug
Study: NCT05883137

Intervention type: DEVICE
Intervention: Optiflow Switch
Description: High flow nasal oxygen with the Optiflow Switch device
Study: NCT05764798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental group: Shugan Jieyu Capsule combined with zolpidem
Description: Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group: Placebo combined with zolpidem
Description: Placebo and zolpidem orally for 8 consecutive weeks
Study: NCT06554613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
Study: NCT06017063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
Study: NCT06027320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Education
Description: Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alzheimer Disease Education
Description: Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
Study: NCT06041529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Study: NCT05684523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05547555

Intervention type: DIAGNOSTIC_TEST
Intervention: embryo selection
Description: The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A

Intervention type: DIAGNOSTIC_TEST
Intervention: embryo selection
Description: The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
Study: NCT06179212

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Tests
Description: Patients will complete 4 different cardiopulmonary exercise tests in random order.
Study: NCT04550546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: 600,000 U/mL of nystatin in a rinse suspension
Study: NCT04791969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: Intermittent Oral Naltrexone, 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intermittent Oral Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ecological Momentary Intervention
Description: Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use.
Study: NCT04936672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking and Tai Chi Chuan
Description: This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking and Tai Chi Chuan
Description: This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brisk walking and Tai Chi Chuan
Description: This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
Study: NCT06056739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alio platform
Description: Remote monitoring platform
Study: NCT04579068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention of Problematic Alcohol Use
Description: Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
Study: NCT06400602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual ED Care plus Health Coaching
Description: Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual ED Care plus Education
Description: Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
Study: NCT05791825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultivating Healthy Intentional Mindful Educators
Description: The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
Study: NCT05329467

Intervention type: OTHER
Group type: OTHER
Intervention: Validation of Faces Thermomether Scale
Description: Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
Study: NCT05585437

Intervention type: PROCEDURE
Intervention: gastric cancer specialist training program
Description: The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
Study: NCT05382676

Intervention type: DEVICE
Intervention: Eyeswift Pro
Description: assessment of visual function parameters
Study: NCT04818450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 100-300 mg is given to the intervention group
Study: NCT04151563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Specified dose on Specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Specified dose on Specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lucitanib
Description: Specified dose on Specified days
Study: NCT05589636

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bergamot Juice
Description: Bergamot Juice (35% in water)
Study: NCT04841798

Intervention type: OTHER
Group type: OTHER
Intervention: [11C]SL25.1188 PET radiotracer
Description: Monoamine oxidase B (MAO-B) occupancy before and after medication treatment using \[11C\]SL25.1188 PET
Study: NCT05027750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of The Theory of Planned Behaviour For Weight Control
Description: The training to be imparted to the participants was applied online in groups of 5-6 people via the Google Meet program. Obesity training consisting of a total of five sessions. Each session lasted for approximately 30 minutes. After the training given to intervention group, the women will be followed-up for 6 months. The women in the intervention group will be given counseling service by the researchers, and their status will be evaluated every month.
Study: NCT06427681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH006 for injection
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant for injection+Palonosetron hydrochloride injection
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Study: NCT06480474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis
Description: The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis with online forum
Description: Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.